Sanctuary Advisors LLC Sells 268 Shares of Repligen Co. (NASDAQ:RGEN)

Sanctuary Advisors LLC cut its position in shares of Repligen Co. (NASDAQ:RGEN) by 16.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,368 shares of the biotechnology company’s stock after selling 268 shares during the period. Sanctuary Advisors LLC’s holdings in Repligen were worth $197,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Champlain Investment Partners LLC raised its stake in shares of Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock valued at $136,395,000 after acquiring an additional 6,872 shares during the period. Thrivent Financial for Lutherans raised its position in Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after purchasing an additional 36,773 shares in the last quarter. DF Dent & Co. Inc. lifted its stake in Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after purchasing an additional 139,615 shares during the period. Finally, Stephens Investment Management Group LLC boosted its holdings in Repligen by 7.4% during the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock valued at $77,267,000 after purchasing an additional 37,057 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on RGEN. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Canaccord Genuity Group boosted their target price on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Royal Bank of Canada upped their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a report on Friday, February 21st. Finally, StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Trading Up 1.8 %

Shares of NASDAQ RGEN opened at $157.67 on Thursday. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $203.13. The company has a 50-day moving average of $156.74 and a two-hundred day moving average of $148.54. The company has a market cap of $8.83 billion, a PE ratio of -309.16, a P/E/G ratio of 4.54 and a beta of 0.99. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. As a group, equities analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.